The WHO halted hydroxychloroquine trials after the paper appeared, but its authors later withdrew it when Surgisphere blocked an independent audit.

Surgisphere, an obscure Chicago company founded by vascular surgeon Sapan Desai, supplied the database investigators identified as fake behind a Lancet study that helped derail hydroxychloroquine research, Maryanne Demasi reported for the Brownstone Institute.

Harvard cardiologist Mandeep Mehra led the study. Desai, University Hospital Zurich’s Frank Ruschitzka and Amit Patel of the University of Utah and HCA Research Institute joined him as coauthors.

The May 22, 2020, paper claimed to analyze 96,032 hospitalized COVID-19 patients across 671 hospitals on six continents. It linked hydroxychloroquine treatment to higher mortality and dangerous heart rhythms.

The World Health Organization paused the drug’s Solidarity trial arm. Other researchers interrupted trials, and governments changed treatment policies.

The Guardian investigation cited by Demasi found that hospitals in Melbourne and Sydney denied contributing data and said they had never heard of Surgisphere. Its listed staff included a marketing executive who was an adult model and events hostess.

All four authors had declared full access to the data and responsibility for its integrity, Demasi reported.

But Surgisphere refused to give independent reviewers the full dataset, client contracts and an audit report, citing confidentiality. The reviewers withdrew.

“Based on this development, we can no longer vouch for the veracity of the primary data sources,” Mehra, Ruschitzka and Patel stated in the Lancet retraction notice.

Demasi reported that neither journal editors nor peer reviewers had verified the underlying data before the paper influenced global health policy.